Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Madelyn Craig

Interventional Pain Medicine Madison, MS Medical Doctor

NPI 1588169296 CMS profile 11326612

114 Herons Bay Cir, Madison, MS 39110

Open in the dashboard

General payments

$4,738

75 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Madelyn Craig of Madison, MS is reported in the CMS Open Payments database as having received $4,738 across 75 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $409 6
2024 General $450 10
2023 General $2,796 44
2022 General $1,083 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madelyn Craig
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Madelyn Craig were reported at $409. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Madelyn Craig Interventional Pain Medicine median Middle half National median
2019 $0 $684 $216–$2,079 $163
2020 $0 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $1,083 $605 $187–$1,924 $149
2023 $2,796 $671 $195–$1,915 $160
2024 $450 $684 $206–$1,837 $164
2025 $409 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $1,096 17 payments
  2. Abbott Laboratories $1,062 13 payments
  3. Medtronic, Inc. $920 21 payments
  4. Nalu Medical, Inc. $549 6 payments
  5. Nevro Corp. $284 4 payments
  6. Vertos Medical, Inc. $267 3 payments
  7. SPR Therapeutics, Inc $148 1 payment
  8. Spinal Simplicity, LLC $133 1 payment
  9. Averitas Pharma Inc. $112 1 payment
  10. Collegium Pharmaceutical, Inc. $94 4 payments
  11. Other $74 4 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $4,049 72 payments
  2. Travel and Lodging $689 3 payments
Products named General payments · program years 2022–2025
  1. PROCLAIM $1,062 13 payments
  2. INTELLIS ADAPTIVESTIM $920 21 payments
  3. Nalu Neurostimulation System $549 6 payments
  4. WaveWriter Alpha Prime 16 $297 2 payments
  5. mild Device Kit $267 3 payments
  6. General - Pain Management $257 5 payments
  7. General - Therapies $163 1 payment
  8. Senza $159 2 payments
  9. SPRINT PNS System $148 1 payment
  10. HA MINUTEMAN G3-R $133 1 payment
  11. Other $510 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

1,094

Median for Pain Management: 951

Drug cost

$22,203

Median for Pain Management: $26,034

Branded share of claims

33%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 170 $5,494
Buprenorphine Generic 13 $3,407
Lidocaine Generic 17 $3,239
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 173 $3,063
Tizanidine Hcl Generic 187 $1,603
Gabapentin Generic 163 $1,269
Diclofenac Sodium Generic 27 $910
Morphine Sulfate Er Morphine Sulfate Brand 18 $756
Methocarbamol Generic 43 $549
Pregabalin Generic 52 $387

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$98,447

Of which drugs: $30

Medicare patients

102

Average age 71

Services billed

1,400

73 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 31%
Diabetes 30%
Ischemic heart disease 25%
Osteoporosis 24%
Chronic kidney disease 18%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record